Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Fate Therapeutics
Oncternal Therapeutics, Inc
Hutchmed
Incyte Corporation
Zenith Epigenetics
Bristol-Myers Squibb